

CHANGE OF NUMBER OF SHARES AND VOTES IN XBRANE

Xbrane Biopharma AB ("Xbrane" or the "Company") announces changes to the number of shares and votes in the Company. The number of shares and votes in Xbrane have changed following the issue of 21,791 shares during June through exercise of warrants under Warrants series II 2018/2021, adopted at the extra general meeting 2018 and under LTIP 2018, adopted at the annual general meeting 2018.

As of June 30, 2021, the total number of shares and votes in the Company amounts to 22,222,206. The Company's registered share capital amounts to SEK 4,981,908.832925.

Contacts

Martin Åmark, CEO
M: +46 76 309 37 77
E: martin.amark@xbrane.com

Anette Lindqvist, CFO/IR
M: +46 76 325 60 90
E: anette.lindqvist@xbrane.com

About Us

Xbrane Biopharma AB develops biological drugs based on a platform technology that provides significantly lower production costs compared to competing systems. Xbrane's leading product Xlucane™, a Lucentis® biosimilar candidate, addresses the € 10.4bn ophthalmic VEGFa inhibitor market. Marketing authorization of Xlucane™ is expected for the second half of 2022. Xbrane has additionally two biosimilars in its pipeline targeting € 7.9bn in originator sales. Xbrane's head office is in Solna, just outside Stockholm. Xbrane is listed on Nasdaq Stockholm under the ticker XBRANE. For more information, visit www.xbrane.com.

This information is information that Xbrane Biopharma is obliged to make public pursuant to the Financial Instruments Trading Act. The information was submitted for publication at 2021-06-30 12:00 CEST.

Attachments

[CHANGE OF NUMBER OF SHARES AND VOTES IN XBRANE](#)